Mohammed Haneefa Nizamudeen
- Health Canada has authorized Johnson & Johnson’s (NYSE:JNJ) Rybrevant (amivantamab) along with platinum-based chemotherapy as a first-line treatment for non-small cell lung with a certain mutation.
- The authorization is for patients with EGFR Exon 20 insertion mutations.
- The approval was supported by data from the phase 3 PAPILLON study that showed the Rybrevant + chemo combination led to clinically meaningful and statistically significant improvement in progression-free survival and a 60% reduction in the risk of disease progression or death compared to chemo alone.
